These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 24126540)

  • 1. Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells.
    Kawano Y; Kikukawa Y; Fujiwara S; Wada N; Okuno Y; Mitsuya H; Hata H
    Int J Oncol; 2013 Dec; 43(6):1809-16. PubMed ID: 24126540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide.
    Kawano Y; Fujiwara S; Wada N; Izaki M; Yuki H; Okuno Y; Iyama K; Yamasaki H; Sakai A; Mitsuya H; Hata H
    Int J Oncol; 2012 Sep; 41(3):876-84. PubMed ID: 22766978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib reduces the tumorigenicity of multiple myeloma via downregulation of upregulated targets in clonogenic side population cells.
    Nara M; Teshima K; Watanabe A; Ito M; Iwamoto K; Kitabayashi A; Kume M; Hatano Y; Takahashi N; Iida S; Sawada K; Tagawa H
    PLoS One; 2013; 8(3):e56954. PubMed ID: 23469177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines.
    Paíno T; Sarasquete ME; Paiva B; Krzeminski P; San-Segundo L; Corchete LA; Redondo A; Garayoa M; García-Sanz R; Gutiérrez NC; Ocio EM; San-Miguel JF
    PLoS One; 2014; 9(3):e92378. PubMed ID: 24658332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
    Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
    Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.
    Matsui W; Wang Q; Barber JP; Brennan S; Smith BD; Borrello I; McNiece I; Lin L; Ambinder RF; Peacock C; Watkins DN; Huff CA; Jones RJ
    Cancer Res; 2008 Jan; 68(1):190-7. PubMed ID: 18172311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization.
    Udi J; Schüler J; Wider D; Ihorst G; Catusse J; Waldschmidt J; Schnerch D; Follo M; Wäsch R; Engelhardt M
    Br J Haematol; 2013 Apr; 161(1):104-16. PubMed ID: 23384035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells.
    Fuhler GM; Baanstra M; Chesik D; Somasundaram R; Seckinger A; Hose D; Peppelenbosch MP; Bos NA
    Exp Cell Res; 2010 Jul; 316(11):1816-28. PubMed ID: 20307537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
    Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K
    Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells.
    Bhardwaj A; Sethi G; Vadhan-Raj S; Bueso-Ramos C; Takada Y; Gaur U; Nair AS; Shishodia S; Aggarwal BB
    Blood; 2007 Mar; 109(6):2293-302. PubMed ID: 17164350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2.
    Morelli MB; Offidani M; Alesiani F; Discepoli G; Liberati S; Olivieri A; Santoni M; Santoni G; Leoni P; Nabissi M
    Int J Cancer; 2014 Jun; 134(11):2534-46. PubMed ID: 24293211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma.
    Yang H; Robinson SN; Nieto Y; Jones RJ; Gocke CD; Lu J; Giralt SA; Jones RB; Decker WK; Xing D; Steiner D; Champlin RE; McMannis JD; Ng J; Thomas MW; Shah N; Andersson BS; Parmar S; Shpall EJ
    Cancer Res; 2011 Jul; 71(14):5040-9. PubMed ID: 21646477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib influences the expression of malignant plasma cells membrane antigens.
    Tagoug I; Plesa A; Dumontet C
    Eur J Pharmacol; 2013 Apr; 706(1-3):11-6. PubMed ID: 23458070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells.
    Kikuchi J; Koyama D; Mukai HY; Furukawa Y
    Int J Hematol; 2014 Jun; 99(6):726-36. PubMed ID: 24706190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of hypoxia on the pathogenesis and therapy resistance in multiple myeloma.
    Ikeda S; Tagawa H
    Cancer Sci; 2021 Oct; 112(10):3995-4004. PubMed ID: 34310776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD138-negative myeloma cells regulate mechanical properties of bone marrow stromal cells through SDF-1/CXCR4/AKT signaling pathway.
    Wu D; Guo X; Su J; Chen R; Berenzon D; Guthold M; Bonin K; Zhao W; Zhou X
    Biochim Biophys Acta; 2015 Feb; 1853(2):338-47. PubMed ID: 25450979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel-Fe3O4 nanoparticles inhibit growth of CD138(-) CD34(-) tumor stem-like cells in multiple myeloma-bearing mice.
    Yang C; Wang J; Chen D; Chen J; Xiong F; Zhang H; Zhang Y; Gu N; Dou J
    Int J Nanomedicine; 2013; 8():1439-49. PubMed ID: 23610522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma.
    Perez LE; Parquet N; Meads M; Anasetti C; Dalton W
    Eur J Haematol; 2010 Mar; 84(3):212-22. PubMed ID: 19922463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dexamethasone and hypoxia upregulate CXCR4 expression in myeloma cells.
    Kim SW; Kim HY; Lee HJ; Yun HJ; Kim S; Jo DY
    Leuk Lymphoma; 2009 Jul; 50(7):1163-73. PubMed ID: 19391039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.